Abstract. We analyzed the effect of HMG-CoA reductase inhibitors on Ca 2+ release from the sarcoplasmic reticulum (SR) using chemically skinned skeletal muscle fibers from the mouse and the rat. Cerivastatin (>20 m M) released Ca 2+ from the SR, while pravastatin showed only a little effect. The rates of Ca 2+ release were increased by cerivastatin at all Ca 2+ concentrations tested. Cerivastatin-induced Ca 2+ release in the presence of Ca 2+ was affected by adenosine monophosphate, Mg
2+, and procaine in essentially the same way as for caffeine-induced Ca
2+release. The Ca
2+-uptake capacity of the SR was reduced after co-treatment with ryanodine and cerivastatin at pCa 6.0 to a much greater extent than with ryanodine alone. Thus, cerivastatininduced Ca 2+ release in the presence of Ca 2+ must be a result of the activation of the Ca
2+-induced Ca 2+ release (CICR) mechanism of the ryanodine receptor. However, even when CICR was maximally inhibited by Mg 2+ and procaine, or in the practical absence of Ca 2+ (pCa >8), cerivastatin still caused Ca 2+ release. These results indicate that cerivastatin causes Ca 2+ release also by activating some other mechanism(s) in addition to the activation of CICR. Either or both of these effects might be related to its adverse effect, rhabdomyolysis.